Since preparation errors have been reported which have been associated with lack of drug efficacy, including increase of testosterone levels above the castrate level and/or increase of PSA levels [15], eliminating this administrative step could, thus, decrease a potential source of iatrogenic therapeutic inefficiency for the treatment of prostate cancer patients. The gene discussed is KLK3; the disease is prostate cancer.